Modular Medical, Inc.: management transactions · United States · SEC (Form 4)

About Modular Medical, Inc.

Modular Medical, Inc. (NASDAQ: MODD) is a United States-based medical device company headquartered in San Diego, California. For French, Belgian, and Swiss investors, it is best viewed as a micro-cap diabetes-care developer with a focused equity story: simplifying insulin delivery and lowering the barriers to pump adoption for adult patients. The company was founded by Paul DiPerna, a microfluidics engineer and long-time medical device operator who also played a role in the creation of Tandem Diabetes Care. Modular Medical’s roots date back to 2015, and the business later became a public company through a financed shell transaction in 2017, which helps explain its entrepreneurial profile and its still-developing commercial base. The company’s core activity is the design, development, and eventual commercialization of next-generation insulin pump technologies. Its lead product is MODD1, a two-part patch pump intended to be easier to learn, easier to use, and potentially more affordable than some existing alternatives. Modular Medical also references its Pivot platform, which is aligned with the same strategic objective: making insulin delivery less complex and more accessible. At this stage, the company remains a development-stage medical device business rather than a scaled commercial player. As such, the investment case is driven by innovation, regulatory progress, manufacturability, and commercial readiness. Competitively, Modular Medical operates in a diabetes-device market dominated by much larger incumbents with established manufacturing scale, payer relationships, and field sales infrastructure. MODD’s differentiation is not size, but product positioning. The company is targeting adult users who are interested in pump therapy but have historically been discouraged by cost, complexity, or usability concerns. That “accessibility” angle is strategically attractive, but it also means execution risk remains significant, particularly around regulatory timelines, production readiness, and market adoption. Geographically, the business is overwhelmingly U.S.-centric today, with its headquarters and operating base in San Diego, California. Recent disclosures also indicate an intention to pursue foreign regulatory clearance for Pivot, suggesting a longer-term ambition beyond the domestic market, though the near-term focus remains the United States. From a listing perspective, Modular Medical trades on the NASDAQ Capital Market under the ticker MODD, which is important context for investors assessing liquidity and volatility. Recent developments have been centered on capital raising and product advancement. In 2025 and 2026, the company completed or announced multiple equity financings, underscoring the cash-intensive nature of a pre-revenue medtech platform. In 2024, MODD1 received FDA clearance for adult use, a meaningful milestone that validates the product concept and regulatory pathway. However, the company is still working through commercialization preparation, manufacturing improvement, and broader product development. In practical terms, Modular Medical remains a story of optionality: a differentiated diabetes platform with a compelling unmet-need narrative, but one that still must convert regulatory progress into sustainable commercial traction.